Missed Gilead Sciences' Run? What Holders Had To Believe

If Gilead Sciences sat on your watchlist instead of in your account on 1 January 2026, the outcome may feel expensive in hindsight. Investors who held Gilead Sciences from the start of the year are up 28.1%, including dividends. That result lands against a backdrop of bulls arguing that lenacapavir and Trodelvy would serve a growing, aging patient base. The key question is whether that aging demographic assumption was really visible and credible at the outset.

Gilead Sciences is not the only name tied to this theme. Zero in on 33 healthcare AI stocks and compare how each one is priced.

The Argument You Would Have Been Weighing Up On Gilead Sciences

The shares cost US$123 at the start of the period, which meant anyone looking at Gilead Sciences had to decide which story felt more realistic, not which one was guaranteed.

The bullish camp worked off a Fair Value of US$141, essentially the price implied if lenacapavir, Trodelvy and other launches did help Gilead expand into larger, aging HIV and oncology markets. That view leaned on assumptions of 5.6% annual revenue growth and profit margins rising from 20.8% to 32.0% by 2028.

The cautious view anchored on a Fair Value of US$91 and treated Medicare Part D redesign and competitive pressure as key risks. That side assumed HIV sales could be flat near term, Trodelvy might face tougher oncology rivals, and revenue would grow at 1.6% a year with margins reaching 26.8% instead.

What The Gilead Sciences Evidence Actually Tested

Gilead Sciences spent 2026 stacking up data points that leaned toward the optimistic case on growth but kept the profitability debate open. Trodelvy approvals in first line metastatic triple negative breast cancer and the Tubulis and Arcellx deals backed the idea of a broader oncology and aging patient footprint. Reported results told a different story. Revenue reached US$7,803 million in Q2 2026 while the business reported a net loss of US$10,496 million and net margin fell to 134.5% below zero. The period cut both ways.

The takeaway travels well. When a thesis leans on margin expansion from an aging demographic and richer product mix, do not just track sales or new approvals. Instead, watch reported net income and net margin quarter by quarter, and compare them with the original margin path that was used to justify the Fair Value story.

What Gilead Sciences Buyers Are Assuming After The Run

Gilead Sciences now trades at US$153, leaving year-to-date holders up 28.1% from US$123. The selected Narrative’s Fair Value sits below the current price, so it treats that move as front loading a lot of the expected payoff.

That Narrative leans on HIV cash flows and newer oncology and cell therapy assets. For today’s valuation to hold, a buyer must judge that execution on acquisitions, oncology competition and pricing will not derail the multi-platform expansion described.

"Gilead Sciences is a large-cap biopharmaceutical company with a strong cash-generating HIV franchise and an increasingly diversified pipeline across oncology and inflammation. The investment case rests on: Durable HIV cash flows (core earnings engine); next-generation growth platforms (lenacapavir, Trodelvy, cell therapy, immunology); and an aggressive external M&A strategy accelerating pipeline expansion. There may be near-term earnings volatility due to acquisitions, alongside longer-term growth visibility."

The price and this Narrative do not agree. → Uncover what this Narrative says Gilead Sciences is actually worth

Go Straight To The Source

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

• Company 1 - 47% below our estimate - targets record orders for larger LED displays across sports, signage and transit.
• Company 2 - 43% below our estimate - builds premium tea shops as membership data shapes menus, pricing and site selection.
• Company 3 - 30% below our estimate - focuses on turning complex aerospace, defense and healthcare contracts into extended production programs.

Three companies from the same screener. Open the full list of 35 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com